Analysts Offer Predictions for ELEV Q2 Earnings

Elevation Oncology, Inc. (NASDAQ:ELEV) – Leerink Partnrs issued their Q2 2025 earnings estimates for Elevation Oncology in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of ($0.20) per share for the quarter. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.84) per share. Leerink Partnrs also issued estimates for Elevation Oncology’s FY2025 earnings at ($0.85) EPS, FY2026 earnings at ($0.88) EPS and FY2027 earnings at ($1.10) EPS.

Several other equities analysts have also recently commented on ELEV. William Blair initiated coverage on Elevation Oncology in a research note on Friday, January 3rd. They set an “outperform” rating for the company. JMP Securities reiterated a “market outperform” rating and issued a $7.00 target price on shares of Elevation Oncology in a research report on Thursday, December 19th. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Elevation Oncology in a research note on Tuesday, January 14th. Finally, Stephens reissued an “overweight” rating and issued a $5.00 target price on shares of Elevation Oncology in a report on Friday, December 6th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Elevation Oncology currently has an average rating of “Buy” and an average target price of $7.20.

Elevation Oncology Stock Down 1.3 %

Shares of Elevation Oncology stock opened at $0.62 on Monday. The company has a market capitalization of $36.83 million, a PE ratio of -0.76 and a beta of 1.31. Elevation Oncology has a 1-year low of $0.50 and a 1-year high of $5.83. The company has a debt-to-equity ratio of 0.45, a current ratio of 17.77 and a quick ratio of 17.77. The business has a 50-day moving average of $0.65 and a 200-day moving average of $0.74.

Institutional Investors Weigh In On Elevation Oncology

Several institutional investors have recently made changes to their positions in the company. Frazier Life Sciences Management L.P. grew its holdings in Elevation Oncology by 102.6% during the third quarter. Frazier Life Sciences Management L.P. now owns 5,993,579 shares of the company’s stock valued at $3,596,000 after purchasing an additional 3,035,000 shares during the last quarter. Sphera Funds Management LTD. lifted its position in shares of Elevation Oncology by 227.2% during the 3rd quarter. Sphera Funds Management LTD. now owns 1,079,762 shares of the company’s stock worth $648,000 after purchasing an additional 749,762 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Elevation Oncology in the 3rd quarter valued at approximately $260,000. State Street Corp lifted its holdings in shares of Elevation Oncology by 13.5% during the third quarter. State Street Corp now owns 1,018,026 shares of the company’s stock worth $611,000 after buying an additional 120,993 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Elevation Oncology by 7.6% during the third quarter. Geode Capital Management LLC now owns 1,110,085 shares of the company’s stock worth $666,000 after acquiring an additional 78,509 shares during the period. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Elevation Oncology Company Profile

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.